93,639 results match your criteria Estrogen Therapy


Hematology reference intervals for transgender adults on stable hormone therapy.

Clin Chim Acta 2019 Feb 13. Epub 2019 Feb 13.

Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.

Background: The complete blood count (CBC) is a cornerstone of patient care. Several of the normal values for the components of the CBC differ by sex and, therefore, male-specific and female-specific reference intervals are required to interpret these laboratory results. Transgender individuals are often prescribed hormone therapy to affirm their gender, with resulting serum hormone concentrations similar to those of cisgender individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2019.02.011DOI Listing
February 2019

Esophageal metastasis of breast cancer during endocrine therapy for pleural dissemination 21 years after breast surgery: a case report.

Surg Case Rep 2019 Feb 15;5(1):22. Epub 2019 Feb 15.

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Fukuura 3-9, Kanazawa, Yokohama, Kanagawa, 236-0004, Japan.

Background: The esophageal metastasis of breast cancer is rare. Moreover, it is extremely unusual for patients to experience the symptoms of esophageal metastasis during their lifetimes. We present a case of dysphagia caused by esophageal metastasis after a long interval following a primary mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0585-xDOI Listing
February 2019

Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.

Eur J Cancer 2019 Feb 12;110:53-61. Epub 2019 Feb 12.

Department of Clinical Sciences Lund, Division of Surgery, Lund University, Lund, Sweden; Department of Surgery and Gastroenterology, Skåne University Hospital, Lund, Sweden.

Aims: The primary aim was to compare 2 years of adjuvant tamoxifen versus no systemic treatment in premenopausal patients with oestrogen receptor (ER)-positive tumours, regarding breast cancer-free interval (BCFi) and distant recurrence-free interval (D-RFi), with 30 years of follow-up and for specified intervals. Moreover, we aimed to investigate the effects of adjuvant tamoxifen on the incidence of secondary malignancies and survival after distant recurrence.

Methods: Premenopausal patients with primary breast cancer were randomised to 2 years of tamoxifen (n = 277) or no systemic treatment (n = 287), irrespective of ER status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.034DOI Listing
February 2019

Genitourinary syndrome of menopause - is the problem solved? State of the art 2018.

Prz Menopauzalny 2018 Dec 31;17(4):168-174. Epub 2018 Dec 31.

1 Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, Warsaw, Poland.

Vulvovaginal atrophy accompanied by lower urinary tract dysfunction related to low levels of estrogen and androgens is labeled as genitourinary syndrome of menopause (GSM). Although this condition affects most postmenopausal women worldwide, it seems to be underdiagnosed and undertreated. Women should be properly advised to choose an adequate treatment modality to improve their quality of life, sexual relationships and social activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pm.2018.81741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372854PMC
December 2018

Diagnostic value of histopathological examination results obtained during screening of patients with diagnosed atypical hyperplasia.

Prz Menopauzalny 2018 Dec 31;17(4):144-148. Epub 2018 Dec 31.

Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.

Vulvovaginal atrophy accompanied by lower urinary tract dysfunction related to low levels of estrogen and androgens is labeled as genitourinary syndrome of menopause (GSM). Although this condition affects most postmenopausal women worldwide, it seems to be underdiagnosed and undertreated. Women should be properly advised to choose an adequate treatment modality to improve their quality of life, sexual relationships and social activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pm.2018.81734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372849PMC
December 2018

PAX8: A Highly Sensitive Marker for the Glands in Extragenital Endometriosis.

Reprod Sci 2019 Feb 14:1933719119828095. Epub 2019 Feb 14.

1 Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan.

In cases of extragenital endometriosis or microscopic endometriosis lesions, pathological diagnosis can be challenging because endometriotic stroma and glands represent only a minor component of fibrotic endometriotic lesions. For better accuracy of diagnosis, the development of a sensitive and specific epithelial marker is beneficial. Previous studies showed that PAX8 is a highly sensitive and specific marker for primary and metastatic Mullerian epithelial tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1933719119828095DOI Listing
February 2019

A comprehensive review of hormonal and biological therapies for endometriosis: latest developments.

Expert Opin Biol Ther 2019 Feb 14. Epub 2019 Feb 14.

a Academic Unit of Obstetrics and Gynecology , Ospedale Policlinico San Martino , Largo R. Benzi 10, 16132 Genoa , Italy.

Introduction: Endometriosis is a chronic benign estrogen dependent disease characterized by the presence of endometriotic glands and stroma outside the uterine cavity. Although combined hormonal contraceptives and progestins, currently available first-line treatments for endometriosis, are efficacious and well tolerated for treating disease-related pain, some women experience partial or no improvement of pain or its recurrence is frequent after discontinuation of the therapies. For these reasons, new drugs are under investigation for the treatment of endometriosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1581761DOI Listing
February 2019

Comparison of breast cancer risk factors among molecular subtypes: A case-only study.

Cancer Med 2019 Feb 14. Epub 2019 Feb 14.

Key Laboratory of Breast Cancer Prevention and Therapy in Ministry of Education, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.

Epidemiological studies have a clear definition of the risk factors for breast cancer. However, it is unknown whether the distribution of these factors differs among breast cancer subtypes. We conducted a hospital-based case-only study consisting of 8067 breast cancer patients basing on the Tianjin Cohort of Breast Cancer Cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2012DOI Listing
February 2019

Association of hormone replacement therapy with increased risk of meningioma in women: A hospital-based multicenter study with propensity score matching.

Asia Pac J Clin Oncol 2019 Feb 13. Epub 2019 Feb 13.

Centre of Systems Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Aim: There is no consensus regarding the association between hormone replacement therapy (HRT) and risk of meningioma so far. We conducted the first study among Chinese female patients to investigate the influence of HRT use on the risk of meningioma.

Methods: We retrospectively collected records of diagnosis of meningioma for women aged 50 years and above during 2011-2016 and dispense of HRT prior to meningioma diagnosis in three tertiary hospitals in China. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ajco.13138
Publisher Site
http://dx.doi.org/10.1111/ajco.13138DOI Listing
February 2019
1 Read

Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.

Int J Cancer 2019 Feb 13. Epub 2019 Feb 13.

Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, the Netherlands.

The androgen receptor (AR) has potential clinical relevance in metastatic breast cancer (mBC) since it might be a treatment target and has been associated with endocrine resistance. A minimal-invasive way to determine AR expression on metastatic tumor cells is by characterization of circulating tumor cells (CTCs). Here, we assessed AR mRNA expression in CTCs (CTC-AR) and in matched primary tumor samples from mBC patients representing different breast cancer subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32209DOI Listing
February 2019

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer.

Cancers (Basel) 2019 Feb 12;11(2). Epub 2019 Feb 12.

Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.

Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence still occur and remain important clinical challenges. A recent study identified TAR (HIV-1) RNA binding protein 2 (TARBP2) as an oncogene that promotes breast cancer metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020210DOI Listing
February 2019

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material.

Breast Cancer Res Treat 2019 Feb 13. Epub 2019 Feb 13.

Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, The Netherlands.

Purpose: The estrogen (ER), progesterone (PR), and HER2 status are essential in guiding treatment decisions in breast cancer patients. In daily life, the ER/PR/HER2 status is expected to be commonly tested twice, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05141-yDOI Listing
February 2019

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.

Rheumatology (Oxford) 2019 Feb 8. Epub 2019 Feb 8.

Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.

Objectives: To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.

Methods: This observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kez014DOI Listing
February 2019
2 Reads

Estradiol Replacement Timing and Obesogenic Diet Effects on Body Composition and Metabolism in Post-menopausal Macaques.

Endocrinology 2019 Feb 7. Epub 2019 Feb 7.

Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Beaverton, OR.

Whether hormone replacement therapy has beneficial metabolic effects in postmenopausal women remains controversial due to between-study differences in menopausal duration, estrogen formulations, and diet. Additionally, animal studies have not reflected the typical human obesogenic, Western-Style Diet (WSD). In this study, we determined the effects of immediate E (ImE) or delayed E treatment on weight and metabolism parameters in old ovo-hysterectomized rhesus macaques consuming a WSD over a 30-month period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/en.2018-00884DOI Listing
February 2019
2 Reads

Raman spectroscopy as a predictive tool for monitoring osteoporosis therapy in a rat model of postmenopausal osteoporosis.

J Mater Sci Mater Med 2019 Feb 12;30(2):25. Epub 2019 Feb 12.

Department of Oncology and Metabolism, Medical School, University of Sheffield, Beech Hill Road, Sheffield, UK.

Pharmacological therapy of osteoporosis reduces bone loss and risk of fracture in patients. Modulation of bone mineral density cannot explain all effects. Other aspects of bone quality affecting fragility and ways to monitor them need to be better understood. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10856-019-6226-x
Publisher Site
http://dx.doi.org/10.1007/s10856-019-6226-xDOI Listing
February 2019
2 Reads

Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.

Oncol Rep 2019 Jan 22. Epub 2019 Jan 22.

Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, P.R. China.

Tamoxifen, a selective estrogen receptor (ER) modulator, is the most widely used endocrine therapy for patients with ER‑positive breast cancer. However, ~30% of tamoxifen‑treated breast cancers do not initially respond to tamoxifen, and neither do they eventually develop tamoxifen resistance. Bcl‑2‑associated athanogene 1 (BAG‑1) is a multifunctional protein that interacts with a wide range of molecules to protect cells from apoptosis otherwise induced by cytotoxic drugs, growth factor withdrawal, radiation and stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.6978DOI Listing
January 2019

Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy.

BMC Cancer 2019 Feb 11;19(1):135. Epub 2019 Feb 11.

Department of Surgery, Tawam Hospital, AlAin, United Arab Emirates.

Background: Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5' promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor-DNA binding domains as direct response elements to estrogen and progesterone that are linked to breast functions or steroid regulation. The study was designed to determine the role of TFF3 in breast cancer chemoresistance with the aim of establishing TFF3 expression as a biomarker for drug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5316-yDOI Listing
February 2019

The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.

JCO Clin Cancer Inform 2019 Feb(3):1-12

1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Purpose: In an upcoming clinical trial at the Moffitt Cancer Center for women with stage 2/3 estrogen receptor-positive breast cancer, treatment with an aromatase inhibitor and a PD-L1 checkpoint inhibitor combination will be investigated to lower a preoperative endocrine prognostic index (PEPI) that correlates with relapse-free survival. PEPI is fundamentally a static index, measured at the end of neoadjuvant therapy before surgery. We have developed a mathematical model of the essential components of the PEPI score to identify successful combination therapy regimens that minimize tumor burden and metastatic potential, on the basis of time-dependent trade-offs in the system. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/CCI.18.00078
Publisher Site
http://dx.doi.org/10.1200/CCI.18.00078DOI Listing
February 2019
2 Reads

Combined hormonal contraceptives for heavy menstrual bleeding.

Cochrane Database Syst Rev 2019 Feb 11;2:CD000154. Epub 2019 Feb 11.

Department of Obstetrics and Gynaecology, University of Auckland, Private Bag 92019, Auckland, New Zealand, 1142.

Background: Menorrhagia or heavy menstrual bleeding (HMB) is an excessive blood loss that impairs a woman's quality of life, either physical, emotional, social or material. It is benign and not associated with pregnancy or any other gynaecological or systemic disease. Medical treatments used to reduce excessive menstrual blood loss (MBL) include prostaglandin synthetase inhibitors, antifibrinolytics, oral contraceptive pills, and other hormones. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD000154.pub3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369862PMC
February 2019
3 Reads

miR-142-3p is a tumor suppressor that inhibits estrogen receptor expression in ER-positive breast cancer.

J Cell Physiol 2019 Feb 11. Epub 2019 Feb 11.

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Estrogen receptors (ERs) are involved in the development of many types of malignant tumors, in particular, breast cancer. Among others, ERs affect cell growth, proliferation, and differentiation. The microRNA (miRNA) miR-142-3p has been shown to inhibit carcinogenesis by regulating various cellular processes, including cell cycle progression, cell migration, apoptosis, and invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.28263DOI Listing
February 2019

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Authors:

Lancet 2019 Feb 7. Epub 2019 Feb 7.

Background: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy.

Methods: To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)33137-4DOI Listing
February 2019

Sex Hormone Replacement Therapy in Periodontology - A Systematic Review.

Oral Dis 2019 Feb 10. Epub 2019 Feb 10.

Department of Stomatology, Federal University of Paraná (UFPR), Curitiba, PR, Brazil.

Objective: To analyse whether sex hormone replacement therapy (HRT) improves periodontal parameters and dental implants osseointegration in humans.

Materials And Methods: Electronic databases and hand searches were performed from June to August 2018 in SciELO, LILACS and PubMed/Medline. Human observational and interventional studies that evaluated the following parameters were included: Clinical Attachment Loss (CAL), Probing Pocket Depth (PPD), Bleeding on Probing (BOP), Radiographic Bone Loss (RBL) or osseointegration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/odi.13059DOI Listing
February 2019
1 Read

Estradiol and progesterone regulate proliferation and apoptosis in colon cancer.

Endocr Connect 2019 Feb 1. Epub 2019 Feb 1.

R Carón, IMBECU, CONICET, Mendoza, 5500, Argentina.

Epidemiological studies describe estrogens as protectors in the development of colon cancer in postmenopausal women treated with hormone replacement therapy. However, the role of progesterone in colon cancer has been minimally studied and the results are controversial. For the above, the objective of this work was to determine the hormonal regulation exerted by natural ovarian steroids on proliferation and apoptosis in an experimental model of colon cancer in ovariectomized rats treated with 17 beta-estradiol and progesterone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-18-0374DOI Listing
February 2019
1 Read

Radiation Therapy After Breast-Conserving Surgery in Women 70 Years of Age and Older: How Wisely Do We Choose?

Ann Surg Oncol 2019 Feb 8. Epub 2019 Feb 8.

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Despite data from randomized trials supporting omission of radiation therapy (RT) for women ≥ 70 years of age with T1, estrogen receptor-positive (ER+) tumors undergoing breast-conserving therapy (BCT), RT usage remains high. We reviewed our institutional experience to determine if risk factors for local recurrence or comorbidities influenced use.

Methods: Women ≥ 70 years of age with T1, ER+, human epidermal growth factor receptor 2-negative (HER2-) tumors undergoing BCT in 2010-2012 were identified from a prospectively maintained database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-07151-4DOI Listing
February 2019
1 Read

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Clin Chem 2019 Feb 8. Epub 2019 Feb 8.

Department of Obstetrics and Gynecology, University Hospital and Medical Faculty of the Heinrich Heine University Düsseldorf, Düsseldorf, Germany;

Introduction: Circulating tumor cells (CTCs) may be used to improve cancer diagnosis, prognosis, and treatment. However, because knowledge regarding CTC biology is limited and the numbers of CTCs and CTC-positive cancer patients are low, progress in this field is slow. We addressed this limitation by combining diagnostic leukapheresis (DLA) and microfluidic enrichment to obtain large numbers of viable CTCs from metastasized breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2018.296814DOI Listing
February 2019
1 Read

Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.

J Exp Clin Cancer Res 2019 Feb 8;38(1):63. Epub 2019 Feb 8.

Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, 108 N. Greene Street, Baltimore, MD, 21201, USA.

Background: Interleukin-11 (IL-11), a dominant IL-6 family cytokine, is involved in tumorigenesis, tumor progression and differentiation in colon cancer cells. IL-11 signaling has been recently identified as a potential therapeutic target in colon cancer. Bazedoxifene, a third- generation selective estrogen modulator approved by the Food and Drug Administration (FDA), is a novel inhibitor of IL-11/GP130 signaling discovered by docking modeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13046-019-1072-8DOI Listing
February 2019

Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells.

Cancers (Basel) 2019 Feb 6;11(2). Epub 2019 Feb 6.

Departamento de Química Biológica, Facultad de Ciencias Químicas, CIQUIBIC CONICET, Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba X5000HUA, Argentina.

Antiestrogenic adjuvant treatments are first-line therapies in patients with breast cancer positive for estrogen receptor (ER+). Improvement of their treatment strategies is needed because most patients eventually acquire endocrine resistance and many others are initially refractory to anti-estrogen treatments. The tumor microenvironment plays essential roles in cancer development and progress; however, the molecular mechanisms underlying such effects remain poorly understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11020189DOI Listing
February 2019

Differential expression of estrogen receptor-α on follicular dendritic cells from patients with grade 1-2 and grade 3 follicular lymphoma.

Hematol Oncol 2019 Feb 8. Epub 2019 Feb 8.

Department of Pathological Diagnostics, Yamagata University Faculty of Medicine, Yamagata, Japan.

Hormone therapy has been used for patients with estrogen receptor alpha (ERα)-positive breast cancers. Recently, some studies reported the expression of ERα on neoplastic cells from B cell lymphomas. However, there has been only one report of ERα expression on the follicular dendritic cells (FDCs) that structurally and functionally support the microenvironment of follicular lymphomas (FLs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2577DOI Listing
February 2019
1 Read

Sacrospinous hysteropexy with a low weight transvaginal polypropylene mesh for treatment of complete uterovaginal eversion.

Int Braz J Urol 2019 Feb 10;45. Epub 2019 Feb 10.

Divisão de Urologia Feminina, Departamento de Cirurgia, Faculdade de Ciências Médicas, Universidaded e Campinas, UNICAMP, Brasil.

Introduction: Pelvic Organ Prolapse (POP) is a common condition in elderly resulting from the weakening of the organ suspension elements of multifactorial origin. It compromises significantly the quality of life and can affect more than 50% of multiparous women. Stage IV prolapse or complete uterovaginal eversion corresponds to 10% of the cases and the only form of curative treatment is the surgical correction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0555DOI Listing
February 2019
1 Read

Estriol inhibits dermcidin isoform-2 induced inflammatory cytokine expression via nitric oxide synthesis in human neutrophil.

Curr Mol Med 2019 Feb 7. Epub 2019 Feb 7.

Post Graduate Department of Biochemistry, Cell & Molecular Therapeutics Laboratory Oriental Institute of Science and Technology, Rangamati, Midnapore, WB, 721102. India.

Background: An increase in the level of cytokines like TNF-α and IL-6 causes the inflammatory surge in acute ischemic heart disease (AIHD).

Objective: A high-level dermcidin isoform-2 (DCN-2) occurrence in AIHD was subjected to determine a possible regulation on cytokines expression.Effect of estrogen to counteract the inflammatory response was determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1566524019666190208095754DOI Listing
February 2019
1 Read

Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

Breast Cancer 2019 Feb 7. Epub 2019 Feb 7.

Department of Breast Surgery, Graduate School of Medicine Kyoto University, Kyoto, Japan.

Background: An association between CYP2D6 polymorphisms and tamoxifen (TAM) efficacy has not been confirmed, partly due to unreliable prediction of active metabolite exposure solely by CYP2D6 activity. The efficacy of TAM dose escalation appears limited in poor TAM metabolizers. Since the chlorine atom on the side chain of toremifene (TOR) prevents 4-hydroxylation by CYP2D6, its contribution to active conversion of TOR is minor. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12282-019-00952-9
Publisher Site
http://dx.doi.org/10.1007/s12282-019-00952-9DOI Listing
February 2019
1 Read

Soy Isoflavones Ameliorate Metabolic and Immunological Alterations of Ovariectomy in Female Wistar Rats: Antioxidant and Estrogen Sparing Potential.

Oxid Med Cell Longev 2019 10;2019:5713606. Epub 2019 Jan 10.

College of Applied Medical Sciences, Department of Medical Laboratory Sciences, University of Bisha, Saudi Arabia.

Hormone replacement therapy (HRT) can alleviate estrogen deficiency symptoms especially during menopause. The present study aimed at investigating the effect of soy isoflavones as HRT on immunological and bone health-related parameters with a special focus on the interactions between immunological status and metabolism. Thirty healthy cyclic female Wistar rats were used in this experiment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5713606DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348823PMC
January 2019
1 Read

Assessment of Ki-67 as a potential biomarker in patients with breast cancer.

J Genet Eng Biotechnol 2018 Dec 10;16(2):479-484. Epub 2018 Mar 10.

Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.

Breast cancer is the most common cancer in females, it accounts for one third of all malignancies affecting women. Appropriate biomarkers play significant role in predicting the prognosis and decide the specific therapy to each patient. In this study we aimed at evaluating the value of Ki-67 as a prognostic marker in breast cancer patients and to analyze the associations between Ki-67 and their clinicopathological parameters. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1687157X183002
Publisher Site
http://dx.doi.org/10.1016/j.jgeb.2018.03.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353752PMC
December 2018
2 Reads

Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.

Sci Rep 2019 Feb 7;9(1):1603. Epub 2019 Feb 7.

Philips Research, High Tech Campus 11, 5656 AE, Eindhoven, The Netherlands.

Signal transduction pathways are important in physiology and pathophysiology. Targeted drugs aim at modifying pathogenic pathway activity, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-38179-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367506PMC
February 2019
2 Reads

Current Strategies for the Management of Locoregional Breast Cancer Recurrence.

Oncology (Williston Park) 2019 01;33(1):19-25

Advances in the treatment of breast cancer have decreased the rate of isolated locoregional recurrences (ILRRs) over time. Surgery, radiation therapy, and systemic therapies are used to manage these failure events and their associated poor prognosis. Operable ipsilateral breast tumor recurrences (IBTRs) are treated by either salvage mastectomy or, in select cases, repeat lumpectomy. Read More

View Article

Download full-text PDF

Source
January 2019
2 Reads

Menopausal Hormone Therapy and Risk of Diverticulitis.

Am J Gastroenterol 2019 Feb;114(2):315-321

Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington, USA.

Introduction: Diverticulitis is a significant cause of morbidity among older women, and little attention has been paid to understanding its etiology. We have shown that menopausal hormone therapy (MHT) is associated with the risk of inflammatory bowel disease. In this study, we prospectively examined the association between MHT and the risk of incident diverticulitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000054DOI Listing
February 2019
1 Read

The overall survival of breast cancer patients without adjuvant therapy.

Surg Today 2019 Feb 7. Epub 2019 Feb 7.

Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

Purpose: There are little data regarding the overall survival (OS) of patients without adjuvant systemic therapy, because most patients have been subject to standardized systemic therapies. We evaluated the baseline risk to facilitate making decisions about adjuvant therapy.

Patients And Methods: A total of 1835 breast cancer patients who did not receive adjuvant systemic therapy between 1964 and 1992 were retrospectively evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00595-019-01775-zDOI Listing
February 2019

Characteristics of adverse events of endocrine therapies among older patients with breast cancer.

Support Care Cancer 2019 Feb 7. Epub 2019 Feb 7.

Breast Oncology Center, Cancer Institute Hospital, Ariake 3-8-31, Koto-ku, Tokyo, 135-8550, Japan.

Purpose: To clarify the profile of adverse events from endocrine therapies in older patients.

Methods: We surveyed 15 subjective symptoms including hot flashes, sweating, knuckle stiffness, knee/shoulder joint pain, limb numbness, lethargy, forgetfulness, depressive state, irritated state, genital bleeding, leukorrhea increase, vaginal dryness, bone fracture, and weight gain by a questionnaire among 2044 patients over 55 years old (total number of answered sheets, 8875) and compared the results according to age (56-69 years old vs. ≥ 70 years old) and type of therapy (aromatase inhibitors (AIs) vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04674-8DOI Listing
February 2019
1 Read

Estrogenic Effect of the Extract of QingYan Formula on Reproductive Tissues in Immature Mice.

Evid Based Complement Alternat Med 2019 8;2019:5493714. Epub 2019 Jan 8.

Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

A Chinese herbal preparation, QingYan formula (QYF), has been used clinically for kidney-invigorating. However, no evidence base links QYF to estrogen replacement therapy. In this study, the estrogenic effects of QingYan formula 70% ethanol extract (QYFE) were investigated in immature mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5493714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341256PMC
January 2019

Sequential [F]FDG-[F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience.

Contrast Media Mol Imaging 2019 8;2019:1307247. Epub 2019 Jan 8.

Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University Vienna, Austria.

The aim of this study was to assess whether sequential multiparametric [F]fluoro-desoxy-glucose ([F]FDG)/[F]fluoromisonidazole ([F]FMISO) PET-MRI in breast cancer patients is possible, facilitates information on tumor heterogeneity, and correlates with prognostic indicators. In this pilot study, IRB-approved, prospective study, nine patients with ten suspicious breast lesions (BIRADS 5) and subsequent breast cancer diagnosis underwent sequential combined [F]FDG/[18F]FMISO PET-MRI. [F]FDG was used to assess increased glycolysis, while [F]FMISO was used to detect tumor hypoxia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/1307247DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341235PMC
January 2019

Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis.

Indian J Clin Biochem 2019 Jan 8;34(1):3-18. Epub 2019 Jan 8.

1Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 342005 India.

Breast cancer is recognized for its different clinical behaviors and patient outcomes, regardless of common histopathological features at diagnosis. The heterogeneity and dynamics of breast cancer undergoing clonal evolution produces cells with distinct degrees of drug resistance and metastatic potential. Presently, single cell analysis have made outstanding advancements, overshadowing the hurdles of heterogeneity linked with vast populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12291-019-0811-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346617PMC
January 2019

Effects of estrogen therapies on outcomes in Turner Syndrome: assessment of induction of puberty and adult estrogen use.

J Clin Endocrinol Metab 2019 Feb 6. Epub 2019 Feb 6.

Reproductive Medicine Unit, University College London Hospital, London, UK.

Context: Turner Syndrome (TS) is often associated with delayed puberty. To induce puberty, estrogen is administered in incremental doses at an age determined by age of presentation. After puberty, various types of maintenance Estrogen Replacement Therapy (ERT) are used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02137DOI Listing
February 2019
2 Reads

A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma.

Oncoimmunology 2019 3;8(3):1558664. Epub 2019 Jan 3.

Comprehensive Cancer Centre, University Medical Centre Groningen and University of Groningen, Groningen, The Netherlands.

This study aimed to establish the number of expression-based molecular subclasses in cutaneous melanoma, identify their dominant biological pathways and evaluate their clinical relevance. To this end, consensus clustering was performed separately on two independent datasets (n = 405 and n = 473) composed of publicly available cutaneous melanoma expression profiles from previous studies. Four expression-based molecular subclasses were identified and labelled 'Oxidative phosphorylation', 'Oestrogen response/p53-pathway', 'Immune' and 'Cell cycle', based on their dominantly expressed biological pathways determined by gene set enrichment analysis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1
Publisher Site
http://dx.doi.org/10.1080/2162402X.2018.1558664DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350693PMC
January 2019
4 Reads

Lower femoral neck bone mineral density (BMD) in elderly women not on statins.

Women Health 2019 Feb 5:1-9. Epub 2019 Feb 5.

a Department of Internal Medicine , UTHealth McGovern Medical School , Houston , Texas , USA.

Coronary artery disease (CAD) and osteoporosis, the two most frequently occurring chronic diseases of aging populations, share many risk factors including lack of estrogen, smoking, and low physical activity. CAD and low bone mineral density (BMD) are strongly associated. Statins, (3-hydroxy-3-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitors), are used to prevent and treat CAD and have been associated with high BMD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03630242.2019.1567646DOI Listing
February 2019
2 Reads

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.

J Clin Oncol 2019 Feb 5:JCO2018787986. Epub 2019 Feb 5.

1 Johns Hopkins University School of Medicine, Baltimore, MD.

Purpose: Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [F]fluorodeoxyglucose positron emission tomography/computed tomography would predict pathologic complete response (pCR) to neoadjuvant pertuzumab and trastuzumab (PT).

Patients And Methods: Patients with stage II/III, estrogen receptor-negative, HER2-positive breast cancer received four cycles of neoadjuvant PT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.7986DOI Listing
February 2019
1 Read

Transcriptome analysis of Luminal Breast Cancer Reveals a Role for LOL in Tumor Progression and Tamoxifen Resistance.

Int J Cancer 2019 Feb 5. Epub 2019 Feb 5.

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Luminal breast cancer (BC) has a sustained risk of late disease recurrence and death. Considerable numbers of patients suffer from anti-endocrine therapy resistance. Here, we identified a novel lncRNA whose expression is high in breast cancer and especially higher in luminal breast cancer, dubbed LOL (lncRNA of luminal), that acts as a natural sponge for let-7 microRNAs to regulate tumor growth and tamoxifen resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32185DOI Listing
February 2019
2 Reads

The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer.

Int J Mol Sci 2019 Feb 4;20(3). Epub 2019 Feb 4.

The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 2010 Sydney, Australia.

Basal-like breast cancer (BLBC) is an aggressive molecular subtype that represents up to 15% of breast cancers. It occurs in younger patients, and typically shows rapid development of locoregional and distant metastasis, resulting in a relatively high mortality rate. Its defining features are that it is positive for basal cytokeratins and, epidermal growth factor receptor and/or c-Kit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20030667DOI Listing
February 2019
1 Read

Reduced camptothecin sensitivity of estrogen receptor-positive human breast cancer cells following exposure to di(2-ethylhexyl)phthalate (DEHP) is associated with DNA methylation changes.

Environ Toxicol 2019 Feb 5. Epub 2019 Feb 5.

Department of Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan.

Di(2-ethylhexyl)phthalate (DEHP) has been considered as an estrogen receptor alpha (ERα) agonist due to its ability to interact with ERα and promote the cell proliferation of ERα-positive breast cancer cells. The impact of DEHP on the chemical therapy in breast cancer is little known. Two breast cancer cell lines, MCF-7 (ERα-dependent) and MDA-MB-231 (ERα-independent) were examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/tox.22694DOI Listing
February 2019
1 Read
3.197 Impact Factor

Sex-specific influence on cardiac structural remodeling and therapy in cardiovascular disease.

Biol Sex Differ 2019 Feb 4;10(1). Epub 2019 Feb 4.

Department of Medical Physiology, Division of Heart and Lungs, University Medical Center, Utrecht, Utrecht University, Yalelaan 50, 3584CM, Utrecht, The Netherlands.

Background: Cardiovascular diseases (CVDs) culminating into heart failure (HF) are major causes of death in men and women. Prevalence and manifestation, however, differ between sexes, since men mainly present with coronary artery disease (CAD) and myocardial infarction (MI), and post-menopausal women predominantly present with hypertension. These discrepancies are probably influenced by underlying genetic and molecular differences in structural remodeling pathways involved in hypertrophy, inflammation, fibrosis, and apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13293-019-0223-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360698PMC
February 2019
2 Reads